Market closedNon-fractional
Geron/GERN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Geron
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Ticker
GERN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Foster City, United States
Employees
141
Website
www.geron.com
Geron Metrics
BasicAdvanced
$2.5B
Market cap
-
P/E ratio
-$0.34
EPS
0.42
Beta
-
Dividend rate
Price and volume
Market cap
$2.5B
Beta
0.42
Financial strength
Current ratio
3.666
Quick ratio
3.611
Long term debt to equity
4.073
Total debt to equity
4.073
Interest coverage (TTM)
-21.38%
Management effectiveness
Return on assets (TTM)
-28.94%
Return on equity (TTM)
-60.04%
Valuation
Price to revenue (TTM)
4,831.081
Price to book
7.36
Price to tangible book (TTM)
7.36
Price to free cash flow (TTM)
-13.597
Growth
Revenue change (TTM)
5.26%
Earnings per share change (TTM)
-0.44%
3-year revenue growth (CAGR)
15.44%
3-year earnings per share growth (CAGR)
6.10%
What the Analysts think about Geron
Analyst Ratings
Majority rating from 7 analysts.
Geron Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$300K
∞%
Net income
-$55M
6.55%
Profit margin
-18,433.33%
-∞%
Geron Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.09
-$0.08
-$0.09
-$0.09
-
Expected
-$0.08
-$0.10
-$0.11
-$0.10
-$0.10
Surprise
8.00%
-18.64%
-14.29%
-7.89%
-
Geron News
AllArticlesVideos
Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
Business Wire·15 hours ago
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 month ago
Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers
Investopedia·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Geron stock?
Geron (GERN) has a market cap of $2.5B as of July 27, 2024.
What is the P/E ratio for Geron stock?
The price to earnings (P/E) ratio for Geron (GERN) stock is 0 as of July 27, 2024.
Does Geron stock pay dividends?
No, Geron (GERN) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Geron dividend payment date?
Geron (GERN) stock does not pay dividends to its shareholders.
What is the beta indicator for Geron?
Geron (GERN) has a beta rating of 0.42. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Geron stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.